INSM Quote, Financials, Valuation and Earnings

Liquidia has a net margin of -276.42% compared to Insmed's net margin of -1229.71%. Insmed's return on equity of -1146.32% beat Liquidia's return on equity of -165.38%.

Insmed has a consensus price target of $108.45, signalling upside risk potential of 9.85%. On the other hand Liquidia has an analysts' consensus of $30.80 which suggests that it could grow by 118.44%. Given that Liquidia has higher upside potential than Insmed, analysts believe Liquidia is more attractive than Insmed.

Insmed has a beta of 0.798, which suggesting that the stock is 20.181% less volatile than S&P 500. In comparison Liquidia has a beta of 0.036, suggesting its less volatile than the S&P 500 by 96.37%.

Insmed has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Liquidia offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insmed pays -- of its earnings as a dividend. Liquidia pays out -- of its earnings as a dividend.

Insmed quarterly revenues are $92.8M, which are larger than Liquidia quarterly revenues of $3.1M. Insmed's net income of -$256.6M is lower than Liquidia's net income of -$38.4M. Notably, Insmed's price-to-earnings ratio is -- while Liquidia's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insmed is 44.59x versus 80.90x for Liquidia. Usually stocks with elevated PS ratios are considered overvalued.

Recursion Pharmaceuticals has a net margin of -276.42% compared to Insmed's net margin of -1366.49%. Insmed's return on equity of -1146.32% beat Recursion Pharmaceuticals's return on equity of -82.61%.

Insmed has a consensus price target of $108.45, signalling upside risk potential of 9.85%. On the other hand Recursion Pharmaceuticals has an analysts' consensus of $7.57 which suggests that it could grow by 53.89%. Given that Recursion Pharmaceuticals has higher upside potential than Insmed, analysts believe Recursion Pharmaceuticals is more attractive than Insmed.

Insmed has a beta of 0.798, which suggesting that the stock is 20.181% less volatile than S&P 500. In comparison Recursion Pharmaceuticals has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Insmed has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Recursion Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insmed pays -- of its earnings as a dividend. Recursion Pharmaceuticals pays out -- of its earnings as a dividend.

Insmed quarterly revenues are $92.8M, which are larger than Recursion Pharmaceuticals quarterly revenues of $14.8M. Insmed's net income of -$256.6M is lower than Recursion Pharmaceuticals's net income of -$202.5M. Notably, Insmed's price-to-earnings ratio is -- while Recursion Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insmed is 44.59x versus 25.99x for Recursion Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Third Harmonic Bio has a net margin of -276.42% compared to Insmed's net margin of --. Insmed's return on equity of -1146.32% beat Third Harmonic Bio's return on equity of --.

Insmed has a consensus price target of $108.45, signalling upside risk potential of 9.85%. On the other hand Third Harmonic Bio has an analysts' consensus of $4.25 which suggests that it could fall by -21.44%. Given that Insmed has higher upside potential than Third Harmonic Bio, analysts believe Insmed is more attractive than Third Harmonic Bio.

Insmed has a beta of 0.798, which suggesting that the stock is 20.181% less volatile than S&P 500. In comparison Third Harmonic Bio has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Insmed has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Third Harmonic Bio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insmed pays -- of its earnings as a dividend. Third Harmonic Bio pays out -- of its earnings as a dividend.

Insmed quarterly revenues are $92.8M, which are larger than Third Harmonic Bio quarterly revenues of --. Insmed's net income of -$256.6M is lower than Third Harmonic Bio's net income of -$15.8M. Notably, Insmed's price-to-earnings ratio is -- while Third Harmonic Bio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insmed is 44.59x versus -- for Third Harmonic Bio. Usually stocks with elevated PS ratios are considered overvalued.

United Therapeutics has a net margin of -276.42% compared to Insmed's net margin of 40.56%. Insmed's return on equity of -1146.32% beat United Therapeutics's return on equity of 19.92%.

Insmed has a consensus price target of $108.45, signalling upside risk potential of 9.85%. On the other hand United Therapeutics has an analysts' consensus of $382.09 which suggests that it could grow by 33.53%. Given that United Therapeutics has higher upside potential than Insmed, analysts believe United Therapeutics is more attractive than Insmed.

Insmed has a beta of 0.798, which suggesting that the stock is 20.181% less volatile than S&P 500. In comparison United Therapeutics has a beta of 0.574, suggesting its less volatile than the S&P 500 by 42.629%.

Insmed has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. United Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insmed pays -- of its earnings as a dividend. United Therapeutics pays out -- of its earnings as a dividend.

Insmed quarterly revenues are $92.8M, which are smaller than United Therapeutics quarterly revenues of $794.4M. Insmed's net income of -$256.6M is lower than United Therapeutics's net income of $322.2M. Notably, Insmed's price-to-earnings ratio is -- while United Therapeutics's PE ratio is 11.42x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insmed is 44.59x versus 4.61x for United Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.